Obi Umeh, MD, MSc, VP, Franchise Global Program Leader at Takeda, discusses interim results from a study investigating mezagitamab for the treatment of patients with IgA nephropathy. This…
Dana Rizk, MD, professor of medicine at the University of Alabama at Birmingham, discusses the approval of Fabhalta (iptacopan) for adults with IgA nephropathy. Iptacopan, a Factor B…
NEW YORK (Reuters Health) – Androgen suppression therapy – and its attendant side effects — may not be necessary for patients with intermediate-risk prostate cancer treated with combination…
NEW YORK (Reuters Health) – Nearly all patients have complications from chemoradiation for head and neck cancer, a study in the Archives of Otolaryngology: Head and Neck Surgery…
NEW YORK (Reuters Health) – A low platelet count in the presence of hepatitis C viremia indicates the need to begin interferon-based treatment, regardless of the degree of…
NEW YORK (Reuters Health) – Methadone is a safe, effective first- or second-line treatment of cancer pain, even in outpatients, a retrospective study suggests. Concerns over its long…
NEW YORK (Reuters Health) – For men with hot flushes from androgen suppression for prostate cancer, medroxyprogesterone appears to be the best option for relief, according to a…
NEW YORK (Reuters Health) – New research suggests that high-dose vitamin D can be safely given to breast cancer patients with bone metastases, but it will not affect…
Robert Shorr, Ph.D, D.I.C, CEO, Cornerstone Pharmaceuticals, discusses how physicians can understand a new oncology drug, starting with knowing its safety limitations. He also explains the structure and…
NEW YORK (Reuters Health) – Contrary to previous assertions, low total cholesterol is not a cause of cancer, two separate studies show. Furthermore, a lower total cholesterol level…
NEW YORK (Reuters Health) – Neoadjuvant treatment with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor, can help downstage bladder cancer to organ-confined disease, thereby increasing the…
NEW YORK (Reuters Health) – In detecting prostate cancer, no single prostate specific antigen (PSA) cut-off value achieves the likelihood ratios usually required of a screening test, according…
